



## Gene Edited Off-Target Events Identified Through Single-Cell Whole Genome Sequencing



### CRISPR/Cas9 genome editing introduces off-target mutations

Early studies using CRISPR/Cas9 in U2OS.EGFP cells detected off-site mutations at a frequency of 5.6% to 125% (mean of 40%) of on-site mutations, as determined by a T7 Endonuclease I (T7EI) assay<sup>1</sup>. As guide-RNA (gRNA) targeting strategies, Cas9 variants, and predictive off-target algorithms have been developed to improve fidelity (reviewed<sup>2</sup>), off-site mutational frequency has decreased. For example, single-cell whole genome sequencing following CRISPR/Cas9 genome editing of U2OS cells demonstrated the VEGFA gRNA introduced 11 off-target mutations versus one mutation with the EMX1 gRNA<sup>3</sup>.



### CRISPR/Cas9 off-target mutations are variable between individual cells

In cell culture, CRISPR/Cas9 genome editing results in mixed populations of edited and non-edited cells. Comparisons between expanded monoclonal cultures of genome-edited cells reveals different off-target effects. In single-cell whole genome sequencing following CRISPR/Cas9 genome editing of U2OS cells with the VEGFA gRNA, of the 11 off-target mutations observed, only two were recurrent across single cells<sup>3</sup>. Importantly, establishing and passing monoclonal cell lines can further drive the genomic divergence of genome-edited cells<sup>4</sup>.



### CRISPR/Cas9 mutations are detected by single-cell whole genome sequencing

Multiple methods for detecting on- and off-target mutations arising during genome editing have been described, including whole genome sequencing (reviewed<sup>5</sup>). Recently, a new method for whole genome amplification, primary template-directed amplification (PTA), was described<sup>3</sup>. Importantly, PTA enables whole genome sequencing at a single-cell level, facilitating characterization of genome editing on a cell-by-cell basis<sup>3</sup>.

### References

1. Fu et al., "High frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells". *Nat Biotechnol.* (2013)
2. Naeem et al., "Latest Developed Strategies to Minimize the Off-Target Effects in CRISPR-Cas-Mediated Genome Editing". *Cells.* (2020)
3. Gonzalez-Pena et al., "Accurate genomic variant detection in single cells with primary template-directed amplification". *PNAS.* (2021).
4. Panda et al., "Clonally Selected Lines After CRISPR-Cas Editing Are Not Isogenic". *CRISPR J.* (2023)
5. Atkins et al., "Off-Target Analysis in Gene Editing and Applications for Clinical Translation of CRISPR/Cas9 in HIV-1 Therapy". *Front. Genome Ed.* (2021)

*Primary template-directed amplification (PTA) technology is only available in **ResolveDNA**® and **ResolveOME**™ kits.*

## ResolveDNA® and ResolveOME™ Assay Performance

**Table 1: ResolveOME WGS DNA Performance\***

Characteristic	Observed Values
Accuracy	99.5%
Sensitivity	97.1%
Specificity	99.2%
Allelic Balance	98.4%
Genomic Coverage	97.1%

**Table 2: ResolveOME WTS RNA Performance**

Characteristic	Observed Values
Genes Detected	4,546
Reportable Range	6,057
Average Concordance	0.91
Reproducibility (CV)	43.3%

**Table 1: Assay performance characteristics of DNA isolated using ResolveOME.** Analysis of FACS-sorted NA12878 single cells prepared with ResolveOME versus gold-standard reference. WGS: whole genome sequencing.

**Table 2: Assay performance characteristics of RNA isolated using ResolveOME.** Analysis of FACS-sorted NA12878 single cells prepared with ResolveOME versus gold-standard reference WTS: whole transcriptome sequencing.

\*DNA amplified using ResolveDNA and ResolveOME have comparable DNA performance characteristics. All data on file.

### Custom Services

We offer custom service packages from our end-to-end single-cell multiomic pipeline, from singulating cells to ready-to-publish figures. All services include quality control verification. Services include:

- Cell sorting from fresh or frozen cells and tissues
- Whole genome amplification or whole genome and transcriptome amplification
- Library preparation for downstream applications, including whole genome or exome sequencing
- Sequencing of 550M quality reads capturing >97% of the human genome from each cell
- Analysis using our bioinformatics platform, BaseJumper™

### Products

Code	Product	Description
100500	ResolveOME™ Whole Genome and Transcriptome Amplification System	PTA-based kit for accurate and reproducible whole genome and transcriptome amplification.
100545	ResolveDNA® Whole Genome Amplification Kit	PTA-based kit for accurate and reproducible whole genome amplification from single cells and low-input DNA inputs.
100605	BaseJumper™ Bioinformatics Platform	A complete bioinformatics solution for multiomic data analysis and visualization. <a href="https://www.bioskryb.com/basejumper/">https://www.bioskryb.com/basejumper/</a>

*For a complete list of services, products, and pricing, email a member of our team, [info@bioskryb.com](mailto:info@bioskryb.com)*

**BioSkryb**  
GENOMICS

All data on file.

BIOSKRYB, RESOLVEDNA and BASEJUMPER are trademarks of BioSkryb, Inc.

All other product names and trademarks are the property of their respective owners.

© 2023 BioSkryb, Inc. All Rights Reserved

TAS\_043 | 05/2023

[bioskryb.com/custom-services](https://bioskryb.com/custom-services)



For Research Use Only. Not for Use in Diagnostic Procedures.